Advertisement

Topics

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

07:43 EST 11 Feb 2019 | Proactive Investors

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Original Article: Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

NEXT ARTICLE

More From BioPortfolio on "Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...